De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Aileron Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Aileron Therapeutics's winst zal naar verwachting dalen met 34.1% per jaar. De winst per aandeel zal naar verwachting groeien met 13.7% per jaar.

Belangrijke informatie

-34.1%

Groei van de winst

13.7%

Groei van de winst per aandeel

Biotechs winstgroei	28.6%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Aug 2024

Recente toekomstige groei-updates

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

Winst- en omzetgroeiprognoses

NasdaqCM:ALRN - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-62	N/A	N/A	2
12/31/2025	N/A	-35	N/A	N/A	2
12/31/2024	N/A	-25	N/A	N/A	2
6/30/2024	N/A	-25	-26	-26	N/A
3/31/2024	N/A	-18	-20	-20	N/A
12/31/2023	N/A	-16	-20	-20	N/A
9/30/2023	N/A	-13	-14	-14	N/A
6/30/2023	N/A	-17	-19	-19	N/A
3/31/2023	N/A	-24	-22	-22	N/A
12/31/2022	N/A	-27	-25	-25	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-27	-27	N/A
3/31/2022	N/A	-28	-25	-25	N/A
12/31/2021	N/A	-26	-24	-24	N/A
9/30/2021	N/A	-24	-22	-22	N/A
6/30/2021	N/A	-23	-20	-20	N/A
3/31/2021	N/A	-21	-21	-21	N/A
12/31/2020	N/A	-21	-20	-20	N/A
9/30/2020	N/A	-23	-22	-22	N/A
6/30/2020	N/A	-26	-24	-24	N/A
3/31/2020	N/A	-29	-25	-25	N/A
12/31/2019	N/A	-29	-27	-26	N/A
9/30/2019	N/A	-29	-29	-27	N/A
6/30/2019	N/A	-29	-31	-27	N/A
3/31/2019	N/A	-31	-33	-28	N/A
12/31/2018	N/A	-32	-32	-28	N/A
9/30/2018	N/A	-31	-30	-27	N/A
6/30/2018	N/A	-30	-26	-25	N/A
3/31/2018	N/A	-26	N/A	-22	N/A
12/31/2017	N/A	-23	N/A	-21	N/A
9/30/2017	N/A	-20	N/A	-19	N/A
6/30/2017	N/A	-18	N/A	-18	N/A
3/31/2017	N/A	-19	N/A	-17	N/A
12/31/2016	N/A	-18	N/A	-15	N/A
9/30/2016	N/A	-17	N/A	-14	N/A
6/30/2016	N/A	-16	N/A	-12	N/A
3/31/2016	N/A	-14	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-12	N/A
9/30/2015	N/A	-13	N/A	-13	N/A
6/30/2015	N/A	-13	N/A	-12	N/A
3/31/2015	N/A	-15	N/A	-15	N/A
12/31/2014	N/A	-16	N/A	-17	N/A
12/31/2013	22	0	N/A	-14	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ALRN de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ALRN de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ALRN de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van ALRN naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat ALRN volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ALRN naar verwachting over 3 jaar hoog zal zijn

Aileron Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 44% to US$13.00

Price target decreased to US$2.00

Price target decreased to US$2.00

Recent updates

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven